Rifaximin

CHEMBL1617 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

785.9 g/mol

LogP

6.9

Phase

4

A minimally absorbed antibiotic that stays primarily in the gastrointestinal tract, used to treat traveler's diarrhea, reduce recurrent hepatic encephalopathy, and manage irritable bowel syndrome with diarrhea. Because very little enters the bloodstream, it has fewer systemic side effects than other antibiotics.

Molekularmasse

785,9000 g/mol

LogP

6,90

TPSA

198,00 Å²

Lipinski-Regel der Fünf

Nicht bestanden

Therapeutische Bereiche

Non-Small Cell Lung Cancer Alzheimer's Disease Parkinson's Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Obesity Type 2 Diabetes Hypertension Breast Cancer HIV/AIDS Hepatitis C Heart Failure Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C

InChI

InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1

Molecular Formula

C43H51N3O11

HBD / HBA

5 / 12

Rotierbare Bindungen

3

Schwere Atome

57

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A minimally absorbed antibiotic that stays primarily in the gastrointestinal tract, used to treat traveler's diarrhea, reduce recurrent hepatic encephalopathy, and manage irritable bowel syndrome with diarrhea. Because very little enters the bloodstream, it has fewer systemic side effects than other antibiotics.

Yes, Rifaximin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1617. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6436173. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Rifaximin auf PillFYI

Struktur

Schnelldaten

Formel: C43H51N3O11
Synonyme: 1

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.